A New Jersey Judge on Monday tossed a securities fraud class action against drugmaker Aerie Pharmaceuticals and its officers for failing to show that they knowingly misled investors by touting a forthcoming glaucoma medication as a “blockbuster drug.”
The complaint alleged that certain officers and directors of Aerie had violated the Securities Exchange Act of 1934 by overselling the effectiveness of its first drug Rhopressa and omitting some unimpressive trial results for the drug when it was under development.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
